

BIO DEUTSCHLAND

European Business Development Conference

7 – 8 October 2014 | Dresden | Germany

Frank Fliegert

Dr Frank Fliegert currently serves as Global Medical Director at Prima BioMed GmbH, Leipzig, Germany, a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer.

Dr Fliegert studied medicine at the Medical School Hannover, Germany. He received his medical degree in 1993 and went on to specialize in experimental and clinical pharmacology at the University of Aachen, Germany. In 1999, he joined Grünenthal where he gained more than 8 years experience in various R&D positions. Dr Fliegert was focusing on the early clinical development of several NCEs entering the therapeutic areas of acute and chronic pain. The most advanced drug candidate was the opioid analgesic Tapentadol® that has been approved by the FDA in November 2008. Since leaving Grünenthal, Dr Fliegert worked for the Allianz Private Health Insurance, Munich, Germany where he led a group analyzing the cost-effectiveness of drug therapies. In February 2009, he joined NOXXON, Berlin, Germany as Vice President Clinical Development. In this position, he was responsible for the clinical development of three oligonucleotide-based therapeutics targeting inflammatory diseases, hematological disorders and various cancers. These programs have recently been advanced to the stage of clinical proof-of-concept. In 2012, Dr Fliegert joined Boehringer-Ingelheim, Biberach, Germany as Clinical Pharmacology Program Leader. He was involved in the early clinical development strategy of six NCEs in various CNS therapeutic areas. Before joining Prima BioMed in June 2014, Dr Fliegert served as Head of the Clinical Pharmacology Unit at SynteractHCR, Munich, Germany.